Related Experiment Video
Updated: Oct 8, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE
1Department of Oncology and Radiotherapy, University Hospital of Split, School of Medicine, University of Split.
Abstract:
Treatment with androgen deprivation (ADT) has for many years been a standard treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, several phase 3 randomized trials have completely changed the therapeutic approach for these patients. First, two phase 3 trials, CHAARTED and STAMPEDE, showed that docetaxel added to ADT improves survival of patients with mHSPC. Here we present an overview of the most important trials in this setting: STAMPEDE, LATITUDE, ARCHES, ENZAMET and TITAN in which abiraterone acetate, enzalutamide and apalutamide combined with ADT achieved significant improvement in overall survival of patients with mHSPC compared with ADT only. All three agents combined with ADT became new standard of therapy for this group of patients.
